Neurological Diagnostics Fujirebio has a strong focus on neurological diagnostics including FDA-cleared Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio and the acquisition of ADx NeuroSciences, signaling opportunities to partner on blood-based Alzheimer’s disease testing and expansion of biomarker panels.

Strategic Partnerships The company emphasizes partnerships across platforms and with large labs (SRL) and diagnostic firms, offering CDMO services and real-world validation data, which presents sales potential for collaborative development, manufacturing, and distribution agreements.

Infectious and Oncology Growth With ongoing investments in oncology and infectious disease biomarkers and recently expanding collaborations, there are sales opportunities to supply diagnostic content, assays, and validation as Fujirebio scales multi-platform offerings.

Expansion and M&A Recent acquisitions and capacity expansions, including Plasma Services Group and collaborations with Stanford Medicine, indicate a growth trajectory and readiness to onboard new materials, technologies, or development services for IVD customers.

Platform and Tools launches and CE-marked assays such as lumipulse G NfL Blood assay, Neuro Expert Toolbox (NExT) and Lumipulse platform capabilities suggest upsell opportunities for integrated diagnostic workflows, toolsets, and enablement services to diagnostic labs and partners.